During the past decade, Azienda Ospedaliera Ospedali Riuniti Marche Nord conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 12 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 8 clinical trials were completed. i.e. 266.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Ospedali Riuniti Marche Nord" #1 sponsor was "Gilead Sciences" with 4 trials, followed by "Astex Pharmaceuticals, Inc." with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Seagen Inc." with 2 trials sponsored and "Sierra Oncology, Inc." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Ospedali Riuniti Marche Nord" #1 collaborator was "Arcispedale Santa Maria Nuova-IRCCS" with 1 trials as a collaborator, "Azienda Ospedaliero-Universitaria di Parma" with 1 trials as a collaborator, "Centro di Riferimento Oncologico - Aviano" with 1 trials as a collaborator, "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano" with 1 trials as a collaborator and "IRCCS Sacro Cuore Don Calabria di Negrar" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Ospedali Riuniti Marche Nord" are "Leukemia, Myeloid, Acute" (3 trials), "Indolent Non-Hodgkin's Lymphomas" (2 trials), "Myelodysplastic Syndromes" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Anaplastic Large-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Azienda Ospedaliera Ospedali Riuniti Marche Nord" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Ospedali Riuniti Marche Nord" are "Drug" (18 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Idelalisib" (3 trials), "Azacitidine" (2 trials), "Rituximab" (2 trials) and "Treatment Choice" (2 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Ospedali Riuniti Marche Nord" are 18 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Ospedali Riuniti Marche Nord". undefined are not yet recruiting, undefined are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Azienda Ospedaliera Ospedali Riuniti Marche Nord, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Ospedali Riuniti Marche Nord, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Azienda Ospedaliera Ospedali Riuniti Marche Nord has several departments that took part in Clinical trials: "Presidio Ospedaliero San Salvatore - Cardiologia E Utic" - 3 trials, "Ospedale S. Croce Di Fano; Servizio Oncologia" - 2 trials, "Azienda Ospedaliera San Salvatore - Pesaro (Pu) Oncologia Medica" - 2 trials